SPOTLIGHT -
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, discuss the evolving treatment landscape for advanced renal cell carcinoma.
EP. 1: Overview of Renal Cell Carcinoma
EP. 2: Renal Cell Carcinoma Histology and Risk Stratification
EP. 3: Patient Profile: A 67-Year-Old Man With Metastatic Clear Cell RCC
EP. 4: Front Line Trials in Advanced RCC
EP. 5: Considerations in Advanced RCC Treatment Selection
EP. 6: Advanced RCC Treatment Options Post-Progression
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC